Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gedatolisib and PTK7-ADC in Metastatic TNBC
NCT03243331Phase 1Completed
- Start
- Jan 2018
- Primary completion
- May 2020
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of gedatolisib and cofetuzumab pelidotin in triple-negative breast cancer (TNBC) and breast cancer. Primary endpoint: Safety of Gedatolisb + PTK7-ADC using NCI CTCAE v4.0 at 1 year. Started Jan 2018; status: completed.
02
Drugs
gedatolisibcofetuzumab pelidotin
03
Conditions
triple-negative breast cancer (TNBC)breast cancer
Beyond the preview
Go deeper on NCT03243331.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03243331.